Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information

Director of Phase I Clinical Trial Center


PKUCare Luzhong Hospital

Dr. Hou has been engaged in the reserch work in clinical pharmacology and clinical trials of new drugs for nearly 30 years.  In 1989, she served as the director of Phase I and Phase II clinical trial wards at the Institute of Clinical Pharmacology in Beijing Medical University. 


In 2002, she went to the United States as a postdoctoral fellow to conduct cardiovascular clinical pharmacology research and completed a number of clinical evaluations of drug cardiovascular toxicity.


In 2008, she was appointed as the director of Phase I Clinical Trial Center of Teda International Cardiovascular Hospital and the director of Early Clinical Trial of FMD.  Since 2014, Dr. Hou was appointed as the CMO of eStartMed Technology Co., Ltd.  Up to date, she has lead and accomplished more than 100 Phase I new drug clinical trials, bioequivalence trials and dozens of FIH.  All ccomplished trials include: anti-tumor drugs apatinib, pyrrolidine and 19K, etc., diabetes drugs PEX-168 , GLP-1, DDPIV-inhibitor , GKA, etc., and bioequivalence trials (BE) of imatinib, pramipexole, celecoxib, lenalidomide, etc. In 2013 Dr. Hou’s group completed the first domestic TQT clinical trial (Morpholinamide) according to international standards, and multiple IQT (or CQT) studies.


Since 2009, Dr. Hou has participated in the drafting of many guidelines such as CFDA “Guidelines for the Management of Phase I Clinical Trials of Drugs” and “Regulations for Laboratory Management in Analysis of Biological Samples in Drug Clinical Trials”,Issue in December 2011.